To overcome these issues, researchers are focusing on the improvement of the pharmacokinetics of these agents by conjugating an albumin-binding moiety to the PSMA-targeting vector to increase the blood circulation and tumour uptake of the radiopharmaceutical [13–16]. This evidence concerns the gene FOLH1 and neoplasm.